SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is trending following news of a strategic manufacturing partnership to scale production of its Intelligent Fingerprinting Drug Screening Reader, ahead of its anticipated U.S. market entry and promising significant operational benefits. The community is actively debating its low float and short squeeze potential, with many discussing whether recent price action is a "stop raid" for further upside or a sign of an impending offering.

Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.

Sensei Biotherapeutics Inc

Sensei Biotherapeutics (SNSE) is a top trending stock, with intense community discussion centered on its extremely low float and strong potential for a short squeeze. Many traders are actively accumulating shares, comparing it to recent parabolic runners and speculating on a multi-day breakout, especially as the company explores strategic alternatives.

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESHA is trending due to its volatile price action as a low-float SPAC, prompting intense community discussion around its potential for a short squeeze or significant gains. Traders are closely watching its 'tiny float' and high insider ownership, drawing parallels to other recent 'shell company rippers' amidst sharp price swings and trading halts. This speculative interest sees many buying dips and holding, anticipating further explosive moves.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending following its recent FDA approval of NEREUS, the first new motion sickness treatment in over four decades. Community discussion highlights the drug's significant potential beyond its initial indication, particularly its promising application for GLP-1 induced nausea, which many anticipate could unlock a massive market. This approval, coupled with upcoming pipeline catalysts, fuels widespread speculation about a potential buyout from a larger pharmaceutical entity.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is currently trending amidst significant anticipation for a pending Department of Energy announcement regarding awards for surplus plutonium, which could provide the company with crucial, potentially low-cost fuel. The community is actively debating the stock's valuation and the implications of potential zero-cost fuel, with bulls noting signs of institutional accumulation and unusual options activity while bears highlight zero revenue and recent insider selling. This potential award is seen as a game-changer for the small modular reactor company, aligning with the broader demand for carbon-free energy in the AI revolution.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending following recent regulatory updates, including the FDA's priority review for its AXS-05 Alzheimer's disease agitation treatment and progress towards an NDA submission for AXS-12 in narcolepsy. The community is highly optimistic about these developments and continued strong sales of Auvelity, viewing the company as a future leader in CNS therapeutics with significant pipeline potential. This confluence of catalysts has fueled substantial investor enthusiasm, driving the stock to new highs.

🔥 COCK Token – The Ultimate Cross-Chain MemeFi Powerhouse 🔥  In just under 20 days, $COCK has smashed expectations, broken ATHs, and built a project that’s shaking up Cardano and the entire crypto space. 🐓 What Makes $COCK Special?      The Name: Love it or hate it, the energy and engagement it generates are undeniable. The nuance in language and wild appeal set us apart.     #MEMEFI Pioneer: We’re not just another meme coin. $COCK is leading a movement by combining DeFi mechanics, game theory, and community engagement into a groundbreaking ecosystem.     COCKARENA: At the core of our ecosystem is the COCKARENA, a PvP HODL game. Players battle it out, and early exit fees fuel redistributions, burns, and the treasury. This ensures price appreciation and long-term sustainability for loyal holders.  🎰 The COCK Casino  Our casino isn’t just fun—it’s a serious revenue stream for the FLOCK.      Games: Bonanza, Crash, Blackjack, and Roulette (coming soon!).     Impact: Over 7,834 ADA in profits generated within days, directly supporting rewards, burns, and reinvestment.  💰 COCK-ARENA Loans  Unlock liquidity without selling your tokens.      Loan Terms: Borrow up to 30% of your holdings while continuing to earn rewards in the arena.     Investor Focus: Perfect for savvy investors staying in the game while tapping into their holdings.  🤝 Our Insane Partnerships  We’re bridging gaps, building alliances, and breaking barriers across the crypto space. Key Partners:      DANZO: Powering #MEMEFI with Arena, Casino, and Loans.     KLENEK: Interactive training room.     HSKN (Charles Hoskilien): Supporting and starting COCKPIN with 115 AIR NODES for DePIN aggregation. Plans to add APEX and Earth Nodes through a crypto company incorporated in Costa Rica.     ELITE CATS / SNEKKIES / HOT / BANK: Rewarding NFT holders with COCK-LOCK tokens and vice versa.     OCKZ: COCKSOCKS, Golden Cock Ticket (1M COCK), airdrop rewards, and whitelist perks for holders of 200 ADA worth of $COCK.     OLI Partnership:         Content Creation: Lux and the team are crafting engaging educational content about memes and MemeFi for OLi's platform.         Strategic Investment: The OLi Community Trust will invest in $COCK, distributing 100% of rewards to $OLI holders.         Community Reach: Over 22,000 learners will discover $COCK through OLi's gamified ecosystem.     Hi-Rez the Rapper: Expanding reach in marketing and entertainment.     KUNO, CALEB, CADEN, FITY, ROVER, WhaleInsider: Influential collaborators driving crypto adoption and growth.     Cardano Girls: Helping us understand and communicate effectively with ADA’s female audience.     WallStreetBets: Breaking barriers and increasing engagement.     Antonio Brown: Endorsing, supporting, and even playing in the casino and arena!     Advisors:         BERIS, HECKTHESNEK, RTB, CRYPTOGENIUS: Trusted names advising and supporting the project.  Future Partnerships:  More collaborations are in the pipeline to continue expanding engagement and bring new eyes to ADA and CNTs. 🔥 Unmatched Results in Just 20 Days      Supply Burned: 1.65%, worth 148K ADA!     Arena Fees Collected: 54M COCK, worth over 500K ADA, fueling rewards, burns, and partnerships.     Staked COCK-LOCK: 11M COCK-LOCK in the liquid staking platform, with more coming.     Casino Revenue: Skyrocketing profits directly rewarding holders and growing the treasury.     Top Blast Contests: Generated over 120K ADA in volume, rewarding participants with over 50K ADA in prizes.  🌍 Our Vision  To be the most decentralized, rewarding, and innovative token on Cardano while fostering cross-chain collaboration and onboarding the masses.      Breaking Barriers: We’re bringing BTC, ETH, SOL, and other chains into the fold.     Community-Driven: Focused on building bridges and showcasing that crypto can be fun, rewarding, and sustainable.     Expansion: This is just the beginning. With more burns, rewards, and partnerships on the way, $COCK is set to redefine what’s possible in the MemeFi space.  💎 Time in the arena > Timing the market. The FLOCK is unstoppable. Let’s keep breaking walls for Cardano and onboard new users as we take $COCK to new heights.

CockCardano

COCK CRYPTO is a trending topic, driven by its unique real-world utility through the CockyWings LLC food truck business, which generates revenue for token buybacks. Community discussions highlight its newly launched Memes Hub DAPP and liquid staking platform, offering passive gains, solidifying its position as a distinctive asset within the Cardano meme coin space.

The Stellar network is an open source, distributed, and community owned network used to facilitate cross-asset transfers of value. Stellar aims to help facilitate cross-asset transfer of value at a fraction of a penny while aiming to be an open financial system that gives people of all income levels access to low-cost financial services. Stellar can handle exchanges between fiat-based currencies and between cryptocurrencies. Stellar.org, the organization that supports Stellar, is centralized like XRP and meant to handle cross platform transactions and micro transactions like XRP. However, unlike Ripple, Stellar.org is non-profit and their platform itself is open source and decentralized.   Stellar was founded by Jed McCaleb in 2014. Jed McCaleb is also the founder of Mt. Gox and co-founder of Ripple, launched the network system Stellar with former lawyer Joyce Kim. Stellar is also a payment technology that aims to connect financial institutions and drastically reduce the cost and time required for cross-border transfers. In fact, both payment networks used the same protocol initially.  Distributed Exchange Through the use of its intermediary currency Lumens (XLM), a user can send any currency that they own to anyone else in a different currency.  For instance, if Joe wanted to send USD to Mary using her EUR, an offer is submitted to the distributed exchange selling USD for EUR. This submitted offer forms is known as an order book. The network will use the order book to find the best exchange rate for the transaction in-order to minimize the fee paid by a user.  This multi-currency transaction is possible because of "Anchors". Anchors are trusted entities that hold people’s deposits and can issue credit. In essence, Anchors serves as the bridge between different currencies and the Stellar network.  Lumens (XLM) Lumens are the native asset (digital currency) that exist on the Stellar network that helps to facilitate multi-currency transactions and prevent spams. For multi-currency transactions, XLM is the digital intermediary that allows for such a transaction to occur at a low cost.  In-order to prevent DoS attacks (aka spams) that would inevitably occur on the Stellar network, a small fee of 0.00001 XLM is associated with every transaction that occurs on the network. This fee is small enough so it does not significantly affect the cost of transaction, but large enough so it dissuades bad actors from spamming the network.   Prior to Protocol 12, Stellar had a built-in inflation mechanism conceived to allow account holders to collectively direct inflation-generated lumens toward projects built on Stellar.  As the network evolved and grew, it became increasingly clear that inflation wasn’t working as intended — account holders either didn’t set their inflation destination or joined inflation pools to claim the inflation themselves, and the operational costs associated with inflation payments continued to rise — and so a protocol change to disable inflation was proposed, implemented, voted on by validators, and ultimately adopted as part of a network upgrade.  The inflation operation is now deprecated. https://developers.stellar.org/docs/glossary/inflation/

Stellar Lumens

Stellar Lumens is trending amid widespread debate over its value proposition, with strong bearish sentiment calling it "garbage" and a "scam" conflicting with bullish expectations for institutional adoption. Despite community skepticism and calls for further declines, renewed focus on its ISO 20022 compliance and ongoing network developments are fueling optimism for a potential rebound.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics experienced a sharp sell-off after the FDA issued a Complete Response Letter for its relacorilant drug in Cushing's syndrome, seeking additional efficacy evidence despite trial success. This dramatic drop has split the community, with many investors calling it an overreaction given the company's profitable Korlym revenue and extensive pipeline, while others remain wary of further downside amid the regulatory uncertainty.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust is currently trending amid heavy end-of-year profit-taking and tax loss harvesting, leading to widespread discussion about a 'failed Santa rally' and an 'extremely bad close'. Community sentiment is sharply divided, with bulls hoping for a strong rebound in the new year, potentially driven by AI and computing power, while bears anticipate continued volatility and further declines in the upcoming trading period. Many are debating if the current dip is a temporary calendar effect or a precursor to a larger market correction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Swiss pharmaceutical giant Novartis AG were flat on Friday morning in heavy trading volume, despite the company reporting impressive quarterly results.&nbsp;Novartis posted core fourth-quarter (Q4) earnings per share (EPS) of $1.98, up from $1.53 last year, beating the consensus estimate of $1.80.&nbsp;Meanwhile, Q4 revenue reached $13.2 billion, surpassing the previous year’s $11.4 billion and analysts’ expectations of $12.84 billion.The company attributed its strong sales growth to its blockbuster heart-failure drug Entresto and arthritis medication Cosentyx.&nbsp;CEO Vas Narasimhan expressed optimism, stating, “In our first full year as a pure-play innovative medicines company, Novartis delivered one of the strongest financial performances in our history, growing sales 12% cc [constant currency basis] and core operating income 22% cc.”&nbsp;He added that the company achieved key innovation milestones, including new drug approvals and promising data that would drive growth in the mid- to long-term.Despite the upbeat results, retail sentiment on Stocktwits was mixed. Although message volume surged into ‘extremely bullish’ territory, sentiment remained ‘bearish,’ indicating some hesitation among retail traders.&nbsp;<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/NVS_sentiment_and_message_volume_Jan_31_d92ad15174.png" alt="NVS sentiment and message volume Jan 31.png" width="1318" height="324"><figcaption>NVS sentiment and message volume Jan 31 as of 11:45 am ET | source: Stocktwits</figcaption></figure>Novartis is facing upcoming patent expirations for three key drugs, with Entresto expected to face generic competition in the U.S. mid-year.&nbsp;Additionally, two other top-selling drugs, Tasigna for leukemia and Promacta for a blood disorder, will face generics in the U.S.However, Narasimhan reassured investors, emphasizing the company’s “tremendous replacement power” and its ability to bring new treatments to market when patents on existing drugs expire.&nbsp;He also highlighted the company’s strong pipeline, with more than 30 assets that could drive differentiated growth over the long term, including updates on its cardiovascular drug candidate pelacarsen and a key late-stage trial this year.Looking ahead, Novartis forecasted FY25 net sales growth in the mid- to high-single-digit range, with core operating income expected to grow in the high single to low double-digit range.&nbsp;The company also proposed a 6.1% increase in its dividend to 3.50 Swiss francs per share for 2024.Although <a href="https://stocktwits.com/symbol/NVS">Novartis' stock</a> has lost 0.1% over the past 12 months, it is up more than 7% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Novartis company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Novartis Gets Retail Chatting After Upbeat Q4, But Sentiment Stays Tepid Amid Volatile Trading

The company is facing upcoming patent expirations for three key drugs, with Entresto expected to face generic competition in the U.S. mid-year. 

Equity

The company is facing upcoming patent expirations for three key drugs, with Entresto expected to face generic competition in the U.S. mid-year. 


U.S. shares of Sony Group Corp. (<a class="mention" data-mention="$SONY" data-symbol-id="SONY" href="https://stocktwits.com/symbol/SONY" target="_blank">$SONY</a>) surged over 7% pre-market Friday after the company reported a 69% jump in fiscal&nbsp;second-quarter (Q2) profit, driven by strength in its gaming and imaging divisions.&nbsp;Sony posted a profit of 338.5 billion yen (about $2.21 billion) on revenue of 2.91 trillion yen, up 3% year-over-year.&nbsp;The&nbsp;earnings per share (EPS) of 55.86 yen beat the consensus estimate of 39.84 yen, according to FactSet.The company saw robust performance in its Game &amp; Network Services and Imaging &amp; Sensing Solutions segments.&nbsp;Operating profit for the imaging business nearly doubled to 92.41 billion yen due to strong demand for image sensors, though Sony lowered its full-year sales and profit outlook for this segment.&nbsp;Despite selling only 3.8 million PlayStation 5 units this quarter — down from 4.9 million a year ago — Sony raised its annual profit forecast for the game division to 355.0 billion yen from 320.0 billion yen.Sony also launched its upgraded PlayStation 5 Pro this week, ahead of the holiday season, offering enhanced performance over the original 2020 model.&nbsp;The company revised its revenue forecast for the fiscal year ending March 2025, now expecting a 2.4% decline to 12.71 trillion yen, slightly better than the previously forecasted 3.2% drop.&nbsp;However, it maintained its outlook for a modest 1% increase in net profit to 980.0 billion yen.On Stocktwits, Sony was one of the top 30 trending tickers as of 7:30 am ET, reflecting heightened retail interest.&nbsp;<stembedurl>https://stocktwits.com/DT777/message/591690734</stembedurl>Still, Sony’s U.S.-listed shares are down over 2% year-to-date. Meanwhile, Tokyo-listed shares of the firm ended 1.2% higher on Friday.For updates and corrections, email&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>Read next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/usm-tds-stocks-get-upgraded-by-raymond-james/cJ45RFrRaJ">Are USM, TDS Trump Trades Now? Raymond James Upgrades Mid-Cap Telecom Stocks On Reduced Regulatory Risk</a>

Sony also launched its upgraded PlayStation 5 Pro this week, ahead of the holiday season.

Sony Stock Jumps Pre-Market As Profit Booms Nearly 70%: Retail Buzz Builds

Despite selling only 3.8 million PlayStation 5 units this quarter — down from 4.9 million a year ago — Sony raised its annual profit forecast.

AVIV
American Century ETF Trust - Avantis International Large Cap Value ETF

Feed

News

Sentiment

Fundamentals

Info

Latest AVIV News

AVIVAmerican Century ETF Trust - Avantis International Large Cap Value ETF